The U.S. Food and Drug Administration issued a warning letter to Shoolin Pharma Chem LLP, an active pharmaceutical ingredient (API) manufacturer in Gujarat, on August 18, 2026. The letter followed an inspection that identified insanitary production conditions and significant weaknesses in equipment cleaning, laboratory records, stability testing and quality oversight. The agency had also recommended a U.S. market recall, which the company initiated voluntarily on August 4, and placed the firm’s products under an import alert on August 11.
These are documented FDA regulatory actions, not a criminal conviction. The distinction matters because the warning letter records the agency’s findings and the corrective measures it demanded; it does not establish that every medicine made with the company’s ingredients caused patient harm.
When and Where Did the FDA Inspection Take Place?
FDA investigators inspected Shoolin Pharma Chem LLP’s manufacturing facility at Block/Survey No. 408, behind Ratnamani Tubes, near Maruti Inox, Indrad, Mehsana district, Gujarat, from April 13 through April 17, 2026. The facility’s FDA Establishment Identifier is 3038200383. The August 18 warning letter, reference 320-26-116, was addressed to managing directors Dr. Santosh R. Patel and Rajendra C. Patel.
The company manufactured APIs intended for domestic and overseas markets. The FDA specifically identified sildenafil citrate and tadalafil, ingredients used in medicines for erectile dysfunction, among the products manufactured on nondedicated equipment. It said some of the company’s APIs had entered the United States and were used by compounding pharmacies. This made the state of its manufacturing and testing systems directly relevant to U.S. drug safety oversight.
What Sanitation and Equipment Violations Did Investigators Find?
According to the warning letter, inspectors observed unidentified layered residues, corroded equipment surfaces and inadequate gowning near areas where material was processed or packaged. The FDA described leakage and residues on production-area surfaces and transfer equipment. It also documented an employee wearing open-toed sandals in a production area beside exposed equipment.
The concern extended beyond housekeeping. Shoolin used equipment for more than one API but lacked adequate procedures for cleaning and maintaining that equipment. Employees reportedly told investigators that written cleaning and maintenance procedures had not been established, and verification of cleaning through swab or rinse testing had not been performed. Without validated cleaning controls, manufacturers may be unable to show that residues from one product will not contaminate another.
The FDA deemed the drug products adulterated under Section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act because they were prepared, packed or held under insanitary conditions. It also found the APIs adulterated under Section 501(a)(2)(B) because the manufacturing controls did not conform to current good manufacturing practice (CGMP). In this legal context, adulteration can concern manufacturing conditions; it does not require proof that each finished dose was contaminated.
What Was Wrong With the Laboratory Records and Stability Program?
Investigators could not obtain supporting raw data demonstrating that certain tests listed on certificates of analysis had actually been performed. The missing material included laboratory notebooks, analytical records, worksheets and instrument printouts. When a contract laboratory performed tests, Shoolin had issued certificates on its own letterhead without identifying the testing laboratory, according to the FDA.
The stability-testing system also attracted criticism. The company could not provide adequate records supporting labeled expiry periods for sildenafil citrate and tadalafil APIs. Inspectors found sample-storage chambers switched off and, when operated, outside specified temperature or humidity conditions. Certain tadalafil stability samples scheduled for later testing could not be located. Such deficiencies undermine evidence that an API will meet quality requirements throughout its claimed shelf life.
The FDA further found that the quality unit had not adequately overseen testing, cleaning, validation, contract laboratories and annual product reviews. In its May 2 response to an inspection observation report, the company acknowledged deficiencies and promised improvements. The FDA judged that response insufficient because it lacked implemented corrective-action evidence and adequate retrospective risk assessment.
What Recall and Import Restrictions Followed?
The FDA said it recommended recalling all of Shoolin’s APIs then in U.S. distribution during a July 27, 2026 teleconference. The company initiated a voluntary recall on August 4. On August 11, the agency placed all drugs and drug products offered for U.S. import by the firm on Import Alert 66-40. The warning letter states that products appearing to violate CGMP requirements can be detained or refused admission to the United States.
The warning letter also said the FDA could withhold approval of new drug applications or supplements naming the facility as a manufacturer until violations were resolved and compliance confirmed. The possibility of further regulatory action was expressly stated, but the letter itself did not announce a criminal prosecution or a fixed monetary fine.
What Did the FDA Require Shoolin to Do?
The agency called for a comprehensive cleanup and repair plan, photographic evidence of remediation, an independent evaluation of cleaning and cross-contamination risks, and a corrective and preventive action program with measurable deadlines. It also requested a review of data-integrity weaknesses, stability testing and the authority of the quality unit. The firm was advised to engage a qualified CGMP consultant and conduct a broad six-system audit.
Shoolin was instructed to submit a written response within 15 business days of receiving the letter. Future U.S. market access depends on correcting deficiencies and demonstrating that reliable controls operate in practice. As of the warning letter, the FDA’s published findings established substantial manufacturing-compliance problems and ongoing import restrictions, not a verified clinical injury count.
